

Stellingen

Behorende bij het proefschrift

Towards a patient-driven approach to adverse events of targeted agents in oncology

Door Christine Bettine Boers

1. The terminology and classification of oral adverse events associated with targeted therapies has been inconsistent throughout different clinical trials. (*Chapter 2*)
2. To generate evidence based treatment guidelines for targeted therapy-associated oral complaints, controlled trials are needed. (*Chapter 4*)
3. For assessing and grading mucocutaneous adverse events, the dermatological reactions targeted therapy (DERETT) questionnaire should be used. (*Chapter 5*)
4. Despite the fact that an assessment tool seems to be content and linguistically valid, patients' experiences justify further development. (*Chapter 7*)
5. Reporting of harms should be transparent in trials of cancer drugs. (*Gyawali et al., BMJ. 2018;363:k4383.*)
6. The management of erlotinib-associated low grade reactions may be managed with low cost interventions; therefore, it is recommended to give particular attention to low grade reactions for reducing progression to high grade and consequent risk of hospitalization, which really impact on costs. (*Giuliani & Marzola. Cutan Ocul Toxicol. 2013;32(3):248-51*)
7. Time of onset and location of an EGFR inhibitor-associated skin reaction helps to distinguish between papulopustular eruption and bacterial superinfection. (*Braden & Anadkat. Support Care Cancer. 2016;24:3943–50*)
8. Training of healthcare providers in assessing targeted therapy-associated dermatological reactions by using a dermatological atlas may improve inter-observer agreement between dermatologists and oncologists. (*Duffour et al. Eur J Cancer. 2010;46(18):3169-74*)
9. Approach life with humor. As Elbert Hubbard said: "Do not take life too seriously. You will never get out of it alive" (*Elbert Hubbard, 1911*)
10. For a sustainable world, all people need to be crazy. As Steve Jobs said: "The people who are crazy enough to think that they can change the world, are the ones who do". (*Steve Jobs, 1997*)